Loading organizations...
Pfizer is a leading global biopharmaceutical company dedicated to the discovery, development, manufacture, and sale of healthcare products. The company focuses on a diverse portfolio of medicines and vaccines across a broad range of therapeutic areas, including oncology, internal medicine, infectious diseases, inflammation and immunology, and rare diseases. Its approach emphasizes scientific innovation and rigorous research to address unmet medical needs.
The company was founded in 1849 by Charles Pfizer and Charles Erhart in New York City. Their initial venture began with the creation of santonin, an antiparasitic, marking the start of a long history rooted in pharmaceutical manufacturing. The founding insight centered on the potential to produce much-needed chemical compounds and medicinal ingredients at scale.
Pfizer serves patients and healthcare systems worldwide, providing critical treatments and preventative care. The company’s overarching vision is to deliver breakthroughs that change patients' lives, striving to expand what is possible in health and medicine. It continues to pursue advancements that can lead to a healthier global population, driven by a commitment to scientific progress.
Key people at Pfizer.
Pfizer Inc. is a multinational pharmaceutical and biotechnology company that develops, manufactures, and markets a wide range of vaccines, medications, and animal health products for human and veterinary use. It serves patients, healthcare providers, governments, and animal owners worldwide, addressing critical health challenges like infectious diseases, cancer, cardiovascular conditions, and animal welfare through innovative therapies and antibiotics.[1][2][3] From its origins in fine chemicals, Pfizer evolved into a research-driven leader, notably pioneering mass penicillin production during World War II and launching blockbuster drugs like oxytetracycline (Terramycin) and piroxicam (Feldene), with sustained growth through global expansion and acquisitions.[1][2][5]
Pfizer was founded in 1849 in Brooklyn, New York, as Charles Pfizer & Company by German immigrant cousins Charles Pfizer, a chemist, and Charles F. Erhart, a confectioner, with a $2,500 loan from Pfizer's father.[1][2][3][6] They started by producing santonin, an antiparasitic made palatable with a toffee flavor, marking early success in chemical manufacturing.[1][3][8] Pivotal moments included citric acid production via fermentation in 1919 to counter World War I shortages, which enabled penicillin's mass production during World War II, and the 1950 discovery of oxytetracycline, shifting Pfizer to a research-based pharmaceutical giant.[1][2][4] The company incorporated in Delaware in 1942, expanded internationally in the 1950s, entered animal health in 1959, and went public, building on Civil War-era growth supplying painkillers and antiseptics.[1][2][3][5]
Pfizer rides the wave of biopharmaceutical innovation, leveraging biotech advances in fermentation, antibiotics, and vaccines amid rising global health demands from wars, pandemics, and chronic diseases. Its WWII penicillin role treated Allied soldiers, establishing antibiotics as a cornerstone of modern medicine and influencing post-war pharma R&D globally.[1][2][4] Timing mattered: WWI shortages spurred fermentation breakthroughs, while post-WWII penicillin price drops drove diversification into high-margin drugs, aligning with expanding healthcare markets and regulatory shifts favoring research-based firms.[1][2] Market forces like globalization and animal health growth favored Pfizer's early expansions, while its 175-year legacy shapes the ecosystem through tech transfers (e.g., Zoetis spin-off) and R&D investments on three continents, setting standards for scalable drug production.[1][5][9]
Pfizer's trajectory points to deepened biotech integration, with trends like mRNA vaccines, precision medicine, and AI-driven discovery accelerating its pipeline amid aging populations and antimicrobial resistance. Expect influence to grow via strategic acquisitions (e.g., post-Wyeth era) and sustainability in fermentation tech, potentially dominating oncology and rare diseases.[6] As a 175-year pioneer from Brooklyn chemicals to global pharma titan, Pfizer remains primed to innovate lifesaving therapies, echoing its founding commitment.[5][9]
Key people at Pfizer.
Pfizer has 22 tracked investments across 19 companies. The latest tracked deal is $100.0M Series A in Syneron Bio in December 2025.
